Physician profile
John Yoon
NPI 1679839427
$2,414.16
in general payments reported to CMS, 2019-2025
25 companies · $617 in 2025
The $617 reported for 2025 was more than what 85% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $13.09 · 2021: $45.81 · 2022: $465 · 2023: $685 · 2024: $474 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,676 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.47 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $419.29 | 2022-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $324.35 | 2022-2025 | |
| Pfizer INC. | $215.01 | 2019-2025 | |
| Hologic Sales and Service, LLC | $207.36 | 2021-2024 | Myosure Tissue Removal Device, Acessa Provu System, Novasure |
| Organon LLC | $170.81 | 2022-2025 | Nexplanon |
| Evofem Biosciences, INC. | $153.41 | 2022-2025 | Phexxi, Solosec, Phexx |
| Myriad Women'S Health, INC. | $134.10 | 2023 | Myrisk |
| Exeltis, USA INC. | $121.25 | 2020-2025 | Slynd |
| Coopersurgical, INC. | $107.27 | 2023-2024 | Endosee, Paragard T 380a |
| Sumitomo Pharma America, INC. | $104.82 | 2023-2025 | Myfembree, Gemtesa |
| Biogen, INC. | $102.88 | 2025 | Zurzuvae |
| Abbvie INC. | $81.62 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Therapeuticsmd, INC. | $48.77 | 2019 | |
| Shield Therapeutics INC | $48.15 | 2022-2023 | Accrufer |
| Dexcom, INC. | $23.79 | 2025 | Dexcom G6 Transmitter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $23.76 | 2024 | |
| Exact Sciences Corporation | $22.17 | 2023 | Cologuard Collection Kit |
| Gynesonics, INC. | $21.80 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Daiichi Sankyo INC. | $16.65 | 2019 | |
| Sanofi Pasteur INC. | $15.18 | 2025 | |
| Agile Therapeutics, INC. | $14.54 | 2024 | Twirla |
| Mylan Pharmaceuticals INC. | $13.80 | 2019 | |
| Bausch Health US, LLC | $12.42 | 2021 | |
| Mayne Pharma Commercial LLC | $10.96 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Yoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.